First AKT Inhibitor Approved for Advanced Breast Cancer
(MedPage Today) -- The FDA approved the first-in-class AKT inhibitor capivasertib (Truqap), in combination with fulvestrant, for locally advanced/metastatic hormone receptor (HR)-positive/HER2-negative breast cancer and at least one specific genetic...
Source: MedPage Today Public Health - Category: American Health Source Type: news
More News: American Health | Breast Cancer | Cancer | Cancer & Oncology | Genetics | HER2 | Hormones | International Medicine & Public Health